Boeing Defends the Dreamliner and 4 Stocks At 52-Week Highs

AMAG Pharmaceuticals (NASDAQ:AMAG): Closing price $20.85

AMAG Pharmaceuticals has reported positive preliminary data from the IDA-303 study, which is an IDA-303 is a single arm, open-label extension study that evaluated the safety and efficacy of repeat dosing with ferumoxytol in patients suffering from persistent or recurring iron deficiency anemia regardless of the underlying cause and a history of unsatisfactory oral iron therapy, or in whom oral iron could not be used. No new safety signals were seen with repeat dosing of ferumoxytol and the types of reported adverse events were consistent with those seen in both the previously reported IDA and CKD phase III evaluations, and those contained in the approved United States package insert for Feraheme; no hypersensitivity reactions or hypotension were reported in the IDA-303 study. Shares closed up 3.47 percent on Friday at $20.85 and have been traded in a 52-week range of $12.43 to $20.18.